04:20 PM EST, 11/03/2025 (MT Newswires) -- Halozyme Therapeutics ( HALO ) reported Q3 adjusted earnings late Monday of $1.72 per diluted share, up from $1.27 a year earlier.

Analysts polled by FactSet expected $1.63.

Revenue for the three months ended Sept. 30 was $354.3 million, up from $290.1 million a year earlier.

Analysts surveyed by FactSet expected $340 million.

The company adjusted its full-year adjusted EPS guidance to $6.10 to $6.50 from $6 to $6.40 earlier. Analysts expect EPS of $6.13.

The company now expects 2025 revenue of $1.30 billion to $1.38 billion from $1.28 billion to $1.36 billion earlier. Analysts expect $1.32 billion.